Physician profile
Jonathan P Lynch
NPI 1477578599
$3,167.24
in general payments reported to CMS, 2019-2025
33 companies · $746 in 2025
The $746 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $224 · 2021: $100 · 2022: $553 · 2023: $428 · 2024: $945 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $450.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $425.97 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $209.22 | 2022-2025 | |
| Exact Sciences Corporation | $187.36 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $113.73 | 2021-2025 | Mounjaro, Zepbound |
| Pharming Healthcare, INC. | $112.46 | 2019-2024 | Ruconest |
| Corcept Therapeutics | $112.13 | 2024-2025 | Korlym |
| Biocryst US Sales Co., LLC | $93.45 | 2022-2024 | Orladeyo |
| Pfizer INC. | $82.05 | 2019-2025 | |
| Qol Medical, LLC | $73.70 | 2025 | Sucraid |
| Glaxosmithkline, LLC. | $70.72 | 2021-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $61.22 | 2023 | Seglentis, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.93 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $55.65 | 2020-2024 | Takhzyro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.35 | 2023 | Ofev, Jardiance |
| Csl Behring | $52.23 | 2019-2025 | Haegarda, Andembry |
| Dexcom, INC. | $40.00 | 2022 | |
| Allergan, INC. | $35.36 | 2020 | |
| Lundbeck LLC | $26.57 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $25.88 | 2025 | Inspire |
| Teva Pharmaceuticals USA, INC. | $24.51 | 2019 | |
| Amgen INC. | $19.40 | 2024 | Otezla, Repatha |
| Shire North American Group INC | $18.50 | 2019 | |
| Kvk-Tech, INC. | $17.51 | 2019 | |
| Currax Pharmaceuticals LLC | $15.78 | 2024 | Contrave |
| Merck Sharp & Dohme LLC | $14.88 | 2023 | Verquvo, Belsomra |
| Cycle Pharmaceuticals INC | $14.85 | 2025 | Sajazir |
| Biohaven Pharmaceutical Holding Company LTD. | $14.53 | 2022 | |
| Duchesnay USA Incorporated | $14.45 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.81 | 2021 | |
| Genentech USA, INC. | $11.63 | 2019 | |
| Sanofi Pasteur INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.